Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy iCAD stock | 9.03

Own iCAD stock in just a few minutes.


Fact checked

iCAD, Inc is a health information services business based in the US. iCAD shares (ICAD) are listed on the NASDAQ and all prices are listed in US Dollars. iCAD employs 135 staff and has a trailing 12-month revenue of around USD$29.4 million.

How to buy shares in iCAD

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for iCAD. Find the stock by name or ticker symbol: ICAD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iCAD reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$9.03, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of iCAD, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of iCAD. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted iCAD's share price?

Since the stock market crash in March caused by coronavirus, iCAD's share price has had significant negative movement.

Its last market close was USD$9.03, which is 22.42% down on its pre-crash value of USD$11.64 and 52.79% up on the lowest point reached during the March crash when the shares fell as low as USD$5.91.

If you had bought USD$1,000 worth of iCAD shares at the start of February 2020, those shares would have been worth USD$833.89 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,048.74.

iCAD share price

Use our graph to track the performance of ICAD stocks over time.

iCAD shares at a glance

Information last updated 2020-10-20.
Latest market close USD$9.03
52-week range USD$5.91 - USD$15.31
50-day moving average USD$9.6065
200-day moving average USD$10.2899
Wall St. target price USD$14.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.703

Buy iCAD shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy iCAD stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

iCAD price performance over time

Historical closes compared with the close of $9.03 from 2020-11-16

1 week (2020-11-23) -6.04%
1 month (2020-10-30) -7.48%
3 months (2020-08-28) -10.68%
6 months (2020-05-29) -23.08%
1 year (2019-11-29) 20.24%
2 years (2018-11-30) 108.06%
3 years (2017-11-30) 151.53%
5 years (2015-11-30) 121.32%

iCAD financials

Revenue TTM USD$29.4 million
Gross profit TTM USD$24.6 million
Return on assets TTM -14.27%
Return on equity TTM -109.73%
Profit margin -69.88%
Book value $1.158
Market capitalisation USD$223.3 million

TTM: trailing 12 months

Shorting iCAD shares

There are currently 1.1 million iCAD shares held short by investors – that's known as iCAD's "short interest". This figure is 2.7% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting iCAD shares can be evaluated.

iCAD's "short interest ratio" (SIR)

iCAD's "short interest ratio" (SIR) is the quantity of iCAD shares currently shorted divided by the average quantity of iCAD shares traded daily (recently around 244187.75055679). iCAD's SIR currently stands at 4.49. In other words for every 100,000 iCAD shares traded daily on the market, roughly 4490 shares are currently held short.

However iCAD's short interest can also be evaluated against the total number of iCAD shares, or, against the total number of tradable iCAD shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iCAD's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 iCAD shares in existence, roughly 50 shares are currently held short) or 0.0526% of the tradable shares (for every 100,000 tradable iCAD shares, roughly 53 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iCAD.

Find out more about how you can short iCAD stock.

iCAD share dividends

We're not expecting iCAD to pay a dividend over the next 12 months.

Have iCAD's shares ever split?

iCAD's shares were split on a 1:5 basis on 16 August 2012. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iCAD shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for iCAD shares which in turn could have impacted iCAD's share price.

iCAD share price volatility

Over the last 12 months, iCAD's shares have ranged in value from as little as $5.91 up to $15.31. A popular way to gauge a stock's volatility is its "beta".

ICAD.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while iCAD's is 1.3491. This would suggest that iCAD's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

iCAD overview

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer's network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site